Research Paper Volume 12, Issue 18 pp 18545—18560

Figure 6. CI994 reverses the effect of IL-1β in PHCs. (A) mRNA expressions of the chondrogenic markers AGGRECAN, COMP, COL2A1, and SOX9 and the hypertrophic marker COL10A1 in PHCs treated with CI994 (10 nM) at 0, 6, 12, 24, and 48 hours post-treatment. (B) Protein expressions of AGGRECAN and COL2A1 and acetylation of histone H3 (H3_acetyl) in PHCs treated with CI994 (10 nM) at 0, 12, and 48 hours post-treatment. (C) mRNA expressions of the chondrogenic markers AGGRECAN, COMP, COL2A1, and SOX9 and the hypertrophic marker COL10A1 in PHCs treated with 0, 5, 10, 50, and 100 nM CI994 at 12 hours post-treatment. (D) Protein expressions of AGGRECAN and COL2A1 and acetylation of histone H3 (H3_acetyl) in PHCs treated with 0, 10, and 100 nM CI994 at 12 hours post-treatment. (E, F) mRNA expression of MMP-13 in PHCs treated with CI994 (10 nM), IL-1β (5 ng/mL), or the combination of CI994 (10 nM) and IL-1β (5 ng/mL) at 6 and 24 hours post-treatment, respectively. (G) mRNA expressions of AGGRECAN and MMP-13 in PHCs treated with CI994 (10 nM), IL-1β (5 ng/mL), or CI994 (10 nM) plus IL-1β (5 ng/mL) at 24 hours post-treatment. For each experiment, at least three replicates were available for the analysis. Data were expressed as mean ± standard deviation (SD). *P < 0.05; ** P < 0.01; *** P < 0.001.